Literature DB >> 30833666

Systemic oxidative stress in non-arteritic anterior ischemic optic neuropathy.

Serife Birer1, Hatice Arda2, Deniz Kilic3, Gulden Baskol4.   

Abstract

PURPOSE: To investigate whether the serum total oxidant status (TOS), total antioxidant status (TAS), advanced oxidation protein products (AOPP), and thiol parameters could play a role in the pathogenesis of non-arteritic anterior ischemic optic neuropathy (NA-AION).
METHODS: In this study, 18 newly diagnosed NA-AION patients and 17 healthy subjects (control group) were included. Serum plasma TOS and TAS, AOPP, and thiol parameters were measured by spectrophotometric method and the results were compared.
RESULTS: Mean age of the patients and the controls were 60.8 ± 8.4 and 61.9 ± 9.4 years, respectively (p = 0.729). There were no significant differences between the patients and the control group with regard to the values of TAS, TOS, AOPP, and thiol (p = 0.869, p = 0.863, p = 0.040, p = 0.314; respectively). There was a positive correlation between TOS and thiol (p = 0.002, r = 0.681).
CONCLUSION: We found no significant relationship between systemic oxidative parameters and NA-AION. However, this study should be accepted as a pilot investigation and needs to be validated.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30833666      PMCID: PMC6707156          DOI: 10.1038/s41433-019-0388-0

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  28 in total

Review 1.  Nonarteritic anterior ischemic optic neuropathy.

Authors:  Lawrence M Buono; Rod Foroozan; Robert C Sergott; Peter J Savino
Journal:  Curr Opin Ophthalmol       Date:  2002-12       Impact factor: 3.761

2.  Incidence of nonarteritic anterior ischemic optic neuropathy.

Authors:  M G Hattenhauer; J A Leavitt; D O Hodge; R Grill; D T Gray
Journal:  Am J Ophthalmol       Date:  1997-01       Impact factor: 5.258

3.  Programmed cell death of retinal ganglion cells during experimental glaucoma.

Authors:  E Garcia-Valenzuela; S Shareef; J Walsh; S C Sharma
Journal:  Exp Eye Res       Date:  1995-07       Impact factor: 3.467

4.  Protein damage and degradation by oxygen radicals. II. Modification of amino acids.

Authors:  K J Davies; M E Delsignore; S W Lin
Journal:  J Biol Chem       Date:  1987-07-15       Impact factor: 5.157

5.  Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California.

Authors:  L N Johnson; A C Arnold
Journal:  J Neuroophthalmol       Date:  1994-03       Impact factor: 3.042

6.  The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study.

Authors:  Nancy J Newman; Roberta Scherer; Patricia Langenberg; Shalom Kelman; Steven Feldon; David Kaufman; Kay Dickersin
Journal:  Am J Ophthalmol       Date:  2002-09       Impact factor: 5.258

7.  A novel automated method to measure total antioxidant response against potent free radical reactions.

Authors:  Ozcan Erel
Journal:  Clin Biochem       Date:  2004-02       Impact factor: 3.281

Review 8.  Pathogenesis of nonarteritic anterior ischemic optic neuropathy.

Authors:  Anthony C Arnold
Journal:  J Neuroophthalmol       Date:  2003-06       Impact factor: 3.042

9.  Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage.

Authors:  Quan Liu; Won-Kyu Ju; Jonathan G Crowston; Fang Xie; George Perry; Mark A Smith; James D Lindsey; Robert N Weinreb
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-10       Impact factor: 4.799

Review 10.  Ischemic optic neuropathies.

Authors:  Janet C Rucker; Valérie Biousse; Nancy J Newman
Journal:  Curr Opin Neurol       Date:  2004-02       Impact factor: 5.710

View more
  4 in total

1.  Atherogenic indices in non-arteritic ischemic optic neuropathy.

Authors:  Nurullah Koçak; Volkan Yeter; Mustafa Turunç; Merve Bayrambaş; Bilge Eraydın; İnci Güngör
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779

2.  Haematococcus pluvialis-Derived Astaxanthin Is a Potential Neuroprotective Agent against Optic Nerve Ischemia.

Authors:  Wei-Ning Lin; Kishan Kapupara; Yao-Tseng Wen; Yi-Hsun Chen; I-Hong Pan; Rong-Kung Tsai
Journal:  Mar Drugs       Date:  2020-01-28       Impact factor: 5.118

3.  The Protective Effects of n-Butylidenephthalide on Retinal Ganglion Cells during Ischemic Injury.

Authors:  Yu-Yau Chou; Jia-Ying Chien; Jhih-Wei Ciou; Shun-Ping Huang
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

Review 4.  Clinical Applications of Astaxanthin in the Treatment of Ocular Diseases: Emerging Insights.

Authors:  Giuseppe Giannaccare; Marco Pellegrini; Carlotta Senni; Federico Bernabei; Vincenzo Scorcia; Arrigo Francesco Giuseppe Cicero
Journal:  Mar Drugs       Date:  2020-05-01       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.